Home > Insider Trading > Filing (0001209191-22-009564)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1435049	Chinook Therapeutics Inc.	KDNY	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1823187	James Andrew King	C/O Chinook Therapeutics, Inc. 400 Fairview Ave. No., 9Th Floor Seattle WA 98102	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2022-02-10	6,801	$0.00	10,895	No	4	M	Direct
Common Stock	Disposition	2022-02-11	2,498	$12.74	8,397	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units (RSU)	Disposition	2022-02-10	6,801	$0.00	6,801	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
13,605		2024-02-10	No	4	M	Direct

Footnotes

Restricted stock units convert into common stock on a one-for-one basis.
Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.64 to $12.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.
Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 10, 2022, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.